0.9155

0.59% -0.0054

Seres Therapeutics Inc (MCRB)

Overview News Price History Option Chain Financials Discussions Forecast

Seres Therapeutics Inc stock is traded at $0.9155, with a volume of 2.75M. It is down -0.59% in the last 24 hours and up +12.48% over the past month. Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Previous Close:

$0.9209

Open:

$0.93

24h Volume:

2.75M

Relative Volume:

0.78

Market Cap:

$156.31M

Revenue:

$126.33M

Net Income/Loss:

$-82.68M

P/E Ratio:

-0.7383

EPS:

-1.24

Net Cash Flow:

$-79.98M

1W Performance:

+4.20%

1M Performance:

+12.48%

6M Performance:

+21.82%

1Y Performance:

-14.44%

1-Day Range:

$0.9154

$0.962

1-Week Range:

$0.85

$0.9738

52-Week Range:

$0.54

$2.05

Seres Therapeutics Inc Stock (MCRB) Company Profile

Name

Seres Therapeutics Inc

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

617 945 9626

Address

200 SIDNEY STREET, CAMBRIDGE, MA

Employee

233

Twitter

@SeresTX

Next Earnings Date

2024-10-31

Latest SEC Filings

MCRB's Discussions on Twitter

Compare MCRB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MCRB Seres Therapeutics Inc	0.9155	156.31M	126.33M	-82.68M	-79.98M	-0.60
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-24-24	Downgrade	JP Morgan	Neutral → Underweight
Jun-26-23	Resumed	Oppenheimer	Outperform
Apr-21-23	Initiated	JP Morgan	Neutral
Jul-23-21	Downgrade	Goldman	Neutral → Sell
May-18-21	Resumed	Goldman	Neutral
Mar-05-21	Upgrade	Chardan Capital Markets	Neutral → Buy
Sep-18-20	Downgrade	Chardan Capital Markets	Buy → Neutral
Aug-18-20	Initiated	Piper Sandler	Overweight
Aug-11-20	Reiterated	H.C. Wainwright	Buy
Aug-11-20	Upgrade	Jefferies	Hold → Buy
Apr-30-19	Initiated	Jefferies	Hold
Oct-22-18	Initiated	Chardan Capital Markets	Buy
Oct-13-17	Initiated	Oppenheimer	Outperform
Aug-04-17	Reiterated	H.C. Wainwright	Buy
Feb-01-17	Reiterated	FBR & Co.	Outperform
Aug-12-16	Reiterated	FBR Capital	Outperform
Aug-01-16	Downgrade	BofA/Merrill	Buy → Neutral
Aug-01-16	Reiterated	H.C. Wainwright	Buy
Jul-29-16	Resumed	H.C. Wainwright	Buy
Mar-30-16	Initiated	FBR Capital	Outperform
Mar-03-16	Initiated	Guggenheim	Buy
Jan-25-16	Initiated	H.C. Wainwright	Buy
Oct-22-15	Upgrade	BofA/Merrill	Neutral → Buy
Jul-22-15	Initiated	Canaccord Genuity	Buy
Jul-21-15	Initiated	Goldman	Neutral
Jul-21-15	Initiated	Leerink Partners	Outperform

View All

Seres Therapeutics Inc Stock (MCRB) Latest News

Dec 18, 2024

Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 200 Day Moving AverageHere's What Happened - MarketBeat

Dec 18, 2024

Dec 17, 2024

Seres Therapeutics to highlight plans for SER-155 at JPMorgan conference - Yahoo Finance

Dec 17, 2024

Dec 16, 2024

Biotech Biz Xilio Therapeutics Appoints Chief Legal Officer - Law360

Dec 16, 2024

Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer - citybiz

Dec 16, 2024

Xilio Therapeutics Strengthens Leadership Team, Appoints Seres Therapeutics Veteran as Chief Legal Officer - StockTitan

Dec 16, 2024

Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference - The Manila Times

Dec 16, 2024

Seres Therapeutics' Breakthrough Therapy Cuts Infection Risk by 77% in Stem Cell Transplants - StockTitan

Dec 16, 2024

Dec 11, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TTNP, MCRB, LLAP on Behalf of Shareholders - The Eastern Progress Online

Dec 11, 2024

Dec 10, 2024

Seres’ SER-155 gains breakthrough status for BSIs reduction - Yahoo Finance

Dec 10, 2024

Dec 09, 2024

MCRBSeres Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Dec 09, 2024

FDA Grants Breakthrough Therapy Designation to Seres Therapeutics' SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) - The Manila Times

Dec 09, 2024

FDA Grants Breakthrough Therapy Designation to Seres - GlobeNewswire

Dec 09, 2024

Seres' SER-155 Wins FDA Breakthrough Status After Stunning 77% Infection Reduction in Transplant Study - StockTitan

Dec 09, 2024

Nov 27, 2024

Seres Therapeutics (NASDAQ:MCRB) Downgraded to "Sell" Rating by StockNews.com - MarketBeat

Nov 27, 2024

Nov 22, 2024

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference - The Manila Times

Nov 22, 2024

Seres Therapeutics CEO to Present at Piper Sandler Healthcare Conference | MCRB Stock News - StockTitan

Nov 22, 2024

Nov 20, 2024

Seres Therapeutics CEO Eric Shaff sells shares worth $1,354 By Investing.com - Investing.com Nigeria

Nov 20, 2024

Seres Therapeutics Q3 2024 Earnings Preview - MSN

Nov 20, 2024

Seres Therapeutics CEO Eric Shaff sells shares worth $1,354 - Investing.com India

Nov 20, 2024

Nov 19, 2024

Microbiomes Market to Grow by USD 1.13 Billion (2024-2028), Rising Disease Prevalence Driving Revenue, with AI Powering Market EvolutionTechnavio - The Malaysian Reserve

Nov 19, 2024

Seres Therapeutics chief legal officer sells shares worth $474 - Investing.com

Nov 19, 2024

Seres Therapeutics chief legal officer sells shares worth $474 By Investing.com - Investing.com Australia

Nov 19, 2024

Seres Therapeutics executive sells shares worth $397 - Investing.com

Nov 19, 2024

Seres Therapeutics executive sells shares worth $397 By Investing.com - Investing.com Canada

Nov 19, 2024

Nov 18, 2024

Seres Therapeutics Receives Notification from Nasdaq Regarding Bid Price Requirement - Defense World

Nov 18, 2024

Nov 15, 2024

Seres Therapeutics Third Quarter 2024 Earnings: US$0.33 loss per share (vs US$0.37 loss in 3Q 2023) - Yahoo Finance

Nov 15, 2024

Nov 14, 2024

Canaccord Genuity Group Reiterates "Buy" Rating for Seres Therapeutics (NASDAQ:MCRB) - MarketBeat

Nov 14, 2024

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 14, 2024